Corbus Pharmaceuticals Holdings Inc. (CRBP)’s Financial Results Comparing With Cocrystal Pharma Inc. (NASDAQ:COCP)

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) and Cocrystal Pharma Inc. (NASDAQ:COCP) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Corbus Pharmaceuticals Holdings Inc. 2.89M 163.90 49.06M -0.87 0.00
Cocrystal Pharma Inc. N/A 0.00 N/A 0.04 93.68

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Corbus Pharmaceuticals Holdings Inc. and Cocrystal Pharma Inc.


Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Corbus Pharmaceuticals Holdings Inc. -1,697.58% -88.5% -71.2%
Cocrystal Pharma Inc. 0.00% 0.4% 0.4%

Volatility and Risk

Corbus Pharmaceuticals Holdings Inc. is 108.00% more volatile than S&P 500 because the company has a beta of 2.08. In other hand, Cocrystal Pharma Inc. has beta of 1.9 which is 90.00% more volatile than S&P 500.


The Current Ratio of Corbus Pharmaceuticals Holdings Inc. is 3.5 while its Quick Ratio stands at 3.5. The Current Ratio of rival Cocrystal Pharma Inc. is 4.4 and its Quick Ratio is has 4.4. Cocrystal Pharma Inc. is better equipped to clear short and long-term obligations than Corbus Pharmaceuticals Holdings Inc.

Analyst Recommendations

Corbus Pharmaceuticals Holdings Inc. and Cocrystal Pharma Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Corbus Pharmaceuticals Holdings Inc. 0 0 4 3.00
Cocrystal Pharma Inc. 0 0 0 0.00

Corbus Pharmaceuticals Holdings Inc. has a 246.76% upside potential and an average target price of $26.25.

Institutional & Insider Ownership

Corbus Pharmaceuticals Holdings Inc. and Cocrystal Pharma Inc. has shares owned by institutional investors as follows: 44.3% and 8.2%. 3.7% are Corbus Pharmaceuticals Holdings Inc.’s share owned by insiders. Insiders Competitively, owned 67.48% of Cocrystal Pharma Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Corbus Pharmaceuticals Holdings Inc. -2.03% -11.29% 25.19% 15.56% -9.87% -4.79%
Cocrystal Pharma Inc. 1.71% 118.4% 11.25% 24.04% -47.49% -40.67%

For the past year Corbus Pharmaceuticals Holdings Inc. was less bearish than Cocrystal Pharma Inc.


Cocrystal Pharma Inc. beats on 7 of the 11 factors Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases. Its lead product candidate includes JBT-101, a novel oral endocannabinoid-mimetic drug, which is in Phase 2 clinical trials for the treatment of systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis, and systemic lupus erythematosus diseases. The company is based in Norwood, Massachusetts.

Cocrystal Pharma, Inc., a preclinical-stage biopharmaceutical company, focuses on developing antiviral therapeutics for human diseases. The company focuses on developing inhibitors that target viral replication enzymes and viral replication protein. It is developing antiviral therapeutics for human diseases, including hepatitis C virus (HCV), influenza virus, and norovirus. The company also develops targeted in-house chemical libraries consisting of nucleosides, non-nucleoside inhibitors, metal-binding inhibitors, and fragments. It has research collaboration agreement with HitGen, Ltd. and InterX, Inc. to develop small molecule drug candidates against several undisclosed targets. Cocrystal Pharma, Inc. was founded in 2007 and is headquartered in Tucker, Georgia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.